Jan Pinkas - 16 Jul 2025 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (GLYC)

Role
Chief Scientific Officer
Signature
/s/ Barbara Bispham, as attorney-in-fact for Jan Pinkas
Issuer symbol
GLYC
Transactions as of
16 Jul 2025
Net transactions value
$0
Form type
4
Filing time
16 Jul 2025, 19:11:26 UTC
Previous filing
15 Jul 2025
Next filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pinkas Jan Chief Scientific Officer C/O/ CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM /s/ Barbara Bispham, as attorney-in-fact for Jan Pinkas 16 Jul 2025 0002077126

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBIO Stock Option (Right to Buy) Award $0 +142,474 $0.000000 142,474 16 Jul 2025 Ordinary Shares 142,474 $13.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will vest as to 25% on July 7, 2026 and in equal monthly installments thereafter through July 7, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.